Ugolini, A., Zizzari, I. G., Ceccarelli, F., Botticelli, A., Colasanti, T., Strigari, L., . . . Nuti, M. (2020). IgM-Rheumatoid factor confers primary resistance to anti-PD-1 immunotherapies in NSCLC patients by reducing CD137(+)T-cells. EBioMedicine.
シカゴスタイル引用形Ugolini, Alessio, et al. "IgM-Rheumatoid Factor Confers Primary Resistance to Anti-PD-1 Immunotherapies in NSCLC Patients By Reducing CD137(+)T-cells." EBioMedicine 2020.
MLA引用形式Ugolini, Alessio, et al. "IgM-Rheumatoid Factor Confers Primary Resistance to Anti-PD-1 Immunotherapies in NSCLC Patients By Reducing CD137(+)T-cells." EBioMedicine 2020.
警告: この引用は必ずしも正確ではありません.